Ribociclib improves progression-free survival in advanced breast cancer : eurekalert

referring to eurekalert

Ribociclib improves progression-free survival in advanced breast cancer

Ribociclib improves progression-free survival in advanced breast cancer

LUGANO-COPENHAGEN, 8 October, 2016 - The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.The first interim analysis of data from the randomized, double-blind MONALEESA2 study showed a 44% improvement in progression-free survival with ribociclib plus letrozole as a first-line treatment combination."This was THE definitive study to demonstrate the superiority of the combination of ribociclib and letrozole over letrozole alone," said principle investigator, Professor Gabriel Hortobagyi, from the University of Texas MD Anderson Cancer Center in Houston, Texas, US.Researchers randomized 668 postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, who had not undergone any prior systemic treatment, to ribociclib (600 mg/day, 3 weeks on/1 week off) and letrozole (2.5 mg/day, continuous), or letrozole plus placebo.


furthermore columbiamissourian

Salisbury man fighting breast cancer works to boost awareness

Salisbury man fighting breast cancer works to boost awareness

Close Get email notifications on xinxin ou daily!Your notification has been saved.There was a problem saving your notification.Whenever xinxin ou posts new content, you'll get an email delivered to your inbox with a link.


additionally reuters

Novartis challenges Pfizer with strong breast cancer drug data

Novartis challenges Pfizer with strong breast cancer drug data

COPENHAGEN An experimental Novartis pill given with an older drug kept advanced breast cancer in check far longer than standard treatment alone, putting it on track to challenge Pfizer's blockbuster Ibrance, data showed on Saturday.Patients taking ribociclib with letrozole were 44 percent less likely to see their disease progress or to die, a keenly awaited clinical trial found.Novartis' ribociclib works in a similar way to Ibrance and is set to be second to market in the category.It is expected to go on sale next year, ahead of Eli Lilly's rival abemaciclib.